ConcertAI, LLC (ConcertAI), a leading provider of AI software-as-a-service (SaaS) technology and real-world evidence (RWE) solutions for life sciences and healthcare, today announced the appointment of Claudio D’ Ambrosio, PhD, known to be the first Chief Revenue Officer. dr D’Ambrosio, who joined ConcertAI in 2020 as Head of Biopharma Partnerships and RWE Solutions, will lead all biopharma partnership programs and multi-year clinical and post-marketing initiatives.
“When Claudio joined ConcertAI in 2020, he brought with him a deep scientific knowledge and a passion for addressing the greatest unmet medical needs of cancer patients. His experience in research, services, and oncology technologies is unparalleled. In the time he’s been here, Claudio has demonstrated how we can create value for our partners and customers while ensuring ConcertAI can grow in a responsible and sustainable manner,” said Jeff Elton, PhD, CEO of ConcertAI. ” Claudio’s insights have benefited all parts of our business and this expanded role as part of the business leadership team ensures it will continue to be so for years to come.”
“I’m excited to take on this new role at ConcertAI. Over the past two years, I’ve had the opportunity to witness the amazing impact of the company’s solutions and datasets in improving cancer patient outcomes,” said D’Ambrosio. “I look forward to working even more closely with the leadership team and partners to continue to provide new opportunities for biopharma innovators pursuing these outcomes in our next phase of company growth.”
